AK119

DB16423InvestigationalProtein Based Therapies

AK119 is a humanized anti-CD73 monoclonal antibody being investigated in the clinical trial NCT04516564 (A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects).

Mechanism: AK119 binds to, and inhibits, human CD73 with high affinity. It was seen to result in CD73 internalization and promotion of IgG production from B cells in studies. This drug is currently being investigated as immunotherapy for COVID-19.
Curator reviewed · 1 reference
Code names: AK119

Resolves to

Targets

P21589NT5E

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with AK119, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account